ketotifenallergic conjunctivitisкетотифеналлергический конъюнктивит1.Аллергология и иммунология. Национальное руководство. Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа», 2009, 656 с.2.Friedlander M.H. Current ocular therapy. Ed. F.T. Frannfelder, Roy F.H., Randall J., W.B. Saunders Comp. 2000, p. 323.3.Майчук Ю.Ф. Аллергические конъюнктивиты. Рос. мед. журн., 2002, т. 3, № 1, с. 6-10,4.Hingorani M., Calder V., Buckley R.J. and Lightman S. The Role of Conjunctival Epithelial Cells in Chronic Ocular Allergic Disease. Exp. Eye Res. 1998, v. 67, p. 491-500.5.Клинические рекомендации. Офтальмология. Под ред. Л.К. Мошетовой, А.П. Нестерова, Е.А. Егорова. М., «ГЭ-ОТАР-Медиа», 2008, с. 9-43.6.Мачарадзе Д.Ш. Лечение аллергических конъюнктивитов. Леч. Врач. 2008, №4, с. 8-10.7.Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт», 1998, 252 с.8.Schechter B.A. Ketorolac tromethamine 0,4% as a treatment for allergic conjunctivitis. Expert Opin Drug Metab Toxicol. 2008 , v. 4 (4), p. 507-511.9.Grant S.M., Goa K.L., Fitton A. et al. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs, 1990, v. 40, p. 412-448.10.Nabe M., Miyagawa H., Agrawal D.K. et al. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis. Allergy Proc. 1991, v. 12, p. 267-271.11.Miki I., Kusano A., Ohta S. et al. Histamine enhanced the TNF-alpha-induced expression of E-selectin and ICAM-1 on vascular endothelial cells. Cell. Immunol. 1996, v. 171, p. 285-288.12.Abelson M.B., Chambers W.A., Smith L.M. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch. Ophthalmol., 1990, v. 108., p. 84-88.13.Abelson M.B., Chapin M.J., Kapik B.M. et al. Efficacy of ketotifen fumarate 0,025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch. OphthalmoL. 2003, v. 121, p. 626-630.14.Greiner J.V., Mundorf T., Dubiner H. et al. Efficacy and safe W of ketotifen fumarate 0,025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. Am. J. Ophthalmol. 2003, v. 136, p. 1097-1105.15.Crampton H.J. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0,025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Clin. Ther. 2002, v. 24, p. 1800-1808.16.Abelson M.B., Ferzola N.J., McWhirter C.L., Crampton H.J. Efficacy and safe W of single- and multiple-dose ketotifen fumarate 0,025% ophthalmic solution in a pediatric population. PediatrAIlergy Immunol. 2004, v. 15, p. 551-557.17.Mark B. Abelson, Nancy J. Ferzola, Cecilia L. McWhirter, Henry J. Crampton. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0,025% ophthalmic solution in a pediatric population. Pediatr. Allergy Immunol. 2004, v. 15, p. 551-557.18.Kidd M., McKenzie S.H., Steven I. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br. J. Ophthalmol. 2003, v. 87, p. 1206-1211.19.Horak F., Stubner P., Zieglmayer R. et al. Onset and duration of action of ketotifen 0,025% and emedastine 0,05% in seasonal allergic conjunctivitis: efficacy after repeated pollen challenges in the vienna challenge chamber. Clin. Drug. Investig. 2003, v. 23 (5), p. 329-337.20.Borazan M., Karalezli A., Akova Y.A. et al. Efficacy of olopatadine HCI 0,1%, ketotifen fumarate 0,025%, epinastine HCI 0,05%, emedastine 0,05% and fluorometholone acetate 0,1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial Acta Ophthalmol. 2009, v. 87 (5), p. 549-554.21.Цывкина Е.А., Феденко Е. С. Опыт использования глазных капель «Задитен» в лечении конъюнктивитов в практике врача аллерголога. Рос. Аллергол. Журн. 2008, № 2, с. 56-59.